DeCongelio Marc, Ali Sarah N, Furegato Martina, Bhattacharjee Sandipan, Fernandes Ancilla W
Clin Nephrol. 2025 Jan;103(1):19-25. doi: 10.5414/CN111489.
Reliable national estimates for the incidence and prevalence of immunoglobulin A nephropathy (IgAN) in the United States (U.S.) are needed. We performed a national survey with pathologists and used insurance claims data to estimate IgAN frequency nationwide.
An online survey with pathologists was conducted between November and December 2021 to obtain data on the number and types of biopsies evaluated and the proportion with IgAN confirmed. Biopsy data were extrapolated to two different claims databases to estimate incidence and prevalence. Results were validated against a separate dataset of electronic health records.
A total of 43 pathologists from across U.S. regions reported evaluating a mean of 169 kidney biopsies (standard deviation 179.1) in the past 12 months. Of the 7,267 total biopsies evaluated, 632 (8.7%) were IgAN. Based on the respective claims databases, annual incidence rates of 2.1 and 2.2 per 100,000 and prevalence rates of 59.9 and 62.7 per 100,000 were estimated. Results from the validation dataset were similar, with an incidence of 1.9 per 100,000 and prevalence of 54.2 per 100,000.
This study estimated incidence and prevalence of IgAN. Extrapolating the findings to the U.S. population for 2021, total prevalence was 198,887 - 208,184 persons.
需要对美国免疫球蛋白A肾病（IgAN）的发病率和患病率进行可靠的全国性估计。我们对病理学家进行了一项全国性调查，并使用保险理赔数据来估计全国范围内IgAN的发病频率。
在2021年11月至12月期间对病理学家进行了一项在线调查，以获取有关评估的活检数量和类型以及确诊为IgAN的比例的数据。将活检数据外推到两个不同的理赔数据库，以估计发病率和患病率。结果与一个单独的电子健康记录数据集进行了验证。
来自美国各地区的43名病理学家报告称，在过去12个月中平均评估了169例肾活检（标准差179.1）。在总共评估的7267例活检中，632例（8.7%）为IgAN。根据各自的理赔数据库，估计年发病率分别为每10万人2.1例和2.2例，患病率分别为每10万人59.9例和62.7例。验证数据集的结果相似，发病率为每10万人1.9例，患病率为每10万人54.2例。
本研究估计了IgAN的发病率和患病率。将研究结果推算至2021年的美国人口，总患病率为198,887 - 208,184人。
